Videos

Almeida highlighted the increasing prevalence of diabetic macular edema and the importance of developing safe, well-tolerated treatments.

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs).

This large database study explored the link between autoimmune problems and AMD.

In this conversation, Franklin discussed a research study on intraoperative fluorescein angiography in surgical procedures, highlighting significant advancements in surgical visualization and patient outcomes.

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience

At the 2025 ARVO annual meeting, Prof Sadun shared an exciting update in our understanding of Leber hereditary optic neuropathy

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

In cases with optic nerve hyperfluorescence or neurologic symptoms, prompt neuroimaging is warranted to rule out neuro-Behcet disease and guide multidisciplinary management.

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

The trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.

The first SightLine meeting, held pre-ASCRS, reveals insights on physician-industry relationships, mentorship opportunities, and the practical applications of AI in healthcare.

Outcomes from high myopia LASIK using the Teneo laser platform demonstrate strong visual stability and patient satisfaction, with reduced dysphotopsias and minimal reliance on cycloplegia or nomograms.

Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy

The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.

Researchers stratified a dataset of more than 100 patients in an emergency department to see which patients may be indicated for retinal artery occlusions.

Wendy Lee, MD, MS, shares how she integrates aesthetic and functional care in oculoplastics.

At the ARVO 2025 Annual Meeting in Salt Lake City, Utah, Nimesh Patel, MD, presented on the LUCIA and LUGANO phase 3 pivotal trials for EYP-1901 against aflibercept for the treatment of wet macular degeneration.

At the ARVO 2025 meeting in Salt Lake City, Utah, Cameron Cummings presented a poster on how retinal microvascular imaging metrics may show sex-specific biomarkers for Parkinson's disease.

Roshan Kenia presented a poster on how AI-CNet3D enhances glaucoma classification using cross-attention networks while improving interpretability and performance in OCT scan analysis.